1
Ishikawa Rika, Okada Yuji, Kakitani Makoto: Chemically modified granulocyte colony stimulating factor.. Kirin Amgen, December 12, 1990: EP0401384-A1 (353 worldwide citation)

A new chemically modified protein consists of human granulocyte colony stimulating factor (G-CSF) (aminoacid sequence of 174 units ( or 175 with N-terminal methionine) given in the patent) (expressed by host cells from a foreign DNA sequence) bound to polyethylene glycol either through the amino gps ...


2
Cerletti Nico Dr, Mcmaster Gary Kent Dr, Cox David Dr, Schmitz Albert Dr, Meyhack Bernd Dr: Process for the production of biologically active protein (e.g. tgf).. Ciba-Geigy, June 19, 1991: EP0433225-A1 (97 worldwide citation)

The invention relates to a process for the production of biologically active, dimeric TGF- beta , to novel TGF- beta s and pharmaceutical compositions comprising it. TGF- beta produced by this process can be used in various therapeutic modalities.


3
Yamasaki Motoo, Yokoo Yoshiharu, Morimoto Makoto, Okabe Masami: Modified human g-csf.. Kyowa Hakko Kogyo, October 4, 1989: EP0335423-A2 (79 worldwide citation)

A modified polypeptide having human granulocyte colony stimulating factor (hG-CSF) activity comprising a polypeptide having hG-CSF activity with at least one amino group thereof substituted with a group of the formula R1 @OCH2CH2 @nX-R2- (I) wherein R1 is an alkyl or alkanoyl group; n is an optional ...


4
Karasiewicz Robert, Nalin Carlo, Rosen Perry: Peg-interferon conjugates.. Hoffmann La Roche, April 27, 1994: EP0593868-A1 (74 worldwide citation)

The present invention relates to physiologically active water soluble polyethylene glycol conjugates with interferon and to new polyethylene glycol compounds which can be used in the preparation of the conjugates.


5
Camble Roger, Timms David, Wilkinson Anthony James: Continuous release pharmaceutical compositions comprising a polypeptide covalently conjugated to a water soluble polymer.. Ici, March 4, 1992: EP0473268-A2 (67 worldwide citation)

Pharmaceutical compositions for continuous release of a physiologically active substance in which the physiologically active substance comprises a polypeptide covalently conjugated to a water soluble polymer show particularly desirable release characteristics. Polypeptides for use in the pharmaceuti ...


6

7
Cady Susan Mancini, Logan John Steele, Buckwalter Brian Lee, Stockton Gerald W, Chaleff Deborah Tardy: Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization.. American Cyanamid Co, February 28, 1990: EP0355460-A2 (46 worldwide citation)

The present invention relates to novel modified or derivatized recombinant animal somatotropins. This invention also provides methods for stabilizing recombinant animal somatotropins by modification or deletion of the Cysteine residues utilizing site directed mutagenesis to replace from one to four ...


8
Kelman Charles D, Devore Dale P: Human collagen processing and autoimplant use.. Kelman Charles D M D, Devore Dale P, August 30, 1989: EP0330389-A2 (35 worldwide citation)

Production of a chemically modified, crosslinkable, telopeptide-containing, naturally crosslinked, solubilized collagen from tissue obtained from a sole human donor, for implanting in the same donor, by chemically modifying the tissue, e.g. by acylation and/or esterification, to form an autoimplanta ...


9
Seely James E, Yang Ren Der: Method for promoting intramolecular disulfide bond formation in recombinant proteins contained in a denaturant solution.. Pitman Moore, April 19, 1989: EP0312358-A2 (29 worldwide citation)

A method is provided for promoting intramolecular disulfide bond formation in reduced recombinant proteins contained in a denaturant solution. Recombinant proteins which have been solubilized using a denaturant are reacted with an amount of the oxidizing agent cystine sufficient to oxidize free sulf ...


10
Rudolph Rainer Dr, Fischer Stephan Dr, Mattes Ralf Dr: Process for activating recombinant heterologous eucaryotic disulfide-bridged proteins after expression by procaryotes.. Boehringer Mannheim, April 29, 1987: EP0219874-A2 (27 worldwide citation)

Zur Aktivierung von gentechnologisch hergestellten, heterologen, Disulfidbr├╝cken enthaltenden eukaryontischen Proteinen nach Expression in Prokaryonten durch Zellaufschluss, Solubilisierung unter denaturierenden und reduzierenden Bedingungen und Aktivierung unter oxidierenden Bedingungen in Gegenwar ...